Board Member
Atea Pharmaceuticals, Inc. (AVIR)Equibles does not estimate personal net worth.
Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVIR alertsJean-Pierre Sommadossi is recorded as Board Member at Atea Pharmaceuticals, Inc. (AVIR) since January 1, 2014 and CEO at Atea Pharmaceuticals, Inc. (AVIR). The newest filing on record that lists Jean-Pierre Sommadossi as CEO and Board Member at Atea Pharmaceuticals, Inc. (AVIR) is dated April 27, 2026. Jean-Pierre Sommadossi was last confirmed as Board Member at Kezar Life Sciences, Inc. in a filing dated April 29, 2021. The proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $3,403,752 for Jean-Pierre Sommadossi in fiscal 2025, including a base salary of $703,490. Disclosed compensation is on record for 7 fiscal years. Jean-Pierre Sommadossi has spoken on 20 earnings calls and 1 other investor event across 1 company, most recently for Atea Pharmaceuticals, Inc. on September 15, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer), Arthur Kirsch (Board Member) and 7 others.
“So, first I would like to thank Morgan Stanley for the current invitation. I appreciate the opportunity to give an update today of our programs.”
“With two pivotal Phase III top-line readouts for our global Phase III HCV program ahead of us, 2026 will be a catalyst-rich year for Eptaean. We remain on track and are very encouraged by the substantial progress our team continues to achieve.”
“I will begin on slide I am pleased to report that we have made substantial clinical progress in the last year advancing our global Phase III program evaluating the regimen of benifazivir and resazivir for the treatment of HCV infections.”
“The 2020 treatment duration review that we announced today, in addition, antiviral medical need of immunocompromised patients living with hepatitis E infection.”
“For the second quarter, we have several clinical and business highlights to review. We made important progress in our HCV program, evaluating the potential best-in-class regimen of Benefosbury and Roosevelt.”
2014-01-01–present
Last confirmed April 27, 2026
Start not stated–present
Last confirmed April 27, 2026
Kezar Life Sciences, Inc.
Board Member
Proxy statement
2015-01-01–2021-04-29
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member
2014-01-01–present
Kezar Life Sciences, Inc.
Biotechnology · Healthcare
Board Member
Since 2015-01-01, last confirmed 2021-04-29
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $703,490 | $3,403,752 |
| 2024 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $703,490 | $4,202,323 |
| 2023 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $683,000 | $5,925,790 |
| 2022 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $650,000 | $5,878,026 |
| 2021 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $650,000 | $34,104,892 |
| 2020 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $436,862 | $2,886,987 |
| 2019 | Atea Pharmaceuticals, Inc. (AVIR) | President, Chief Executive Officer and Chairman of the Board | $400,000 | $811,080 |
